PERTINENT FINDINGS:99mTc-(HE)3-G3 is safe, is associated with low dose burdens, and enables the differentiation of HER2-positive and HER2-negative primary breast cancer lesions at 2–4 h after injection. This evidence concerns the gene ERBB2 and breast carcinoma.